## **Core Concept**
Hemolytic uremic syndrome (HUS) is a condition characterized by hemolytic anemia, acute kidney failure, and low platelet count. Certain anticancer drugs are known to cause this condition as a side effect. The underlying mechanism often involves damage to the endothelial cells lining blood vessels, leading to microangiopathic hemolytic anemia and renal failure.

## **Why the Correct Answer is Right**
Mitomycin C is a chemotherapeutic agent used in the treatment of various cancers. It works by cross-linking DNA, thereby inhibiting DNA synthesis and function. One of the known side effects of mitomycin C is the induction of hemolytic uremic syndrome (HUS), a condition that can be life-threatening. The mechanism behind mitomycin C-induced HUS is thought to involve endothelial cell damage.

## **Why Each Wrong Option is Incorrect**
* **Option A:** Methotrexate is an antifolate drug used in the treatment of cancer and autoimmune diseases. While it has several side effects, such as myelosuppression and hepatotoxicity, it is not commonly associated with HUS.
* **Option B:** Cisplatin is a platinum-based chemotherapy drug used to treat various types of cancers. Its side effects include nephrotoxicity, neurotoxicity, and ototoxicity, but it is not typically associated with HUS.
* **Option D:** Etoposide is a topoisomerase inhibitor used in cancer chemotherapy. It can cause myelosuppression, alopecia, and gastrointestinal disturbances but is not commonly linked with HUS.

## **Clinical Pearl / High-Yield Fact**
A key clinical pearl to remember is that mitomycin C is a well-documented cause of hemolytic uremic syndrome, especially when used in combination with other chemotherapeutic agents or in high doses. Monitoring for signs of HUS, such as microangiopathic hemolytic anemia and renal dysfunction, is crucial in patients receiving this drug.

## **Correct Answer:** . Mitomycin C